SCNX
Scienture Holdings Inc
$
0.970
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.984
Open
0.984
VWAP
0.96
Vol
165.14K
Mkt Cap
20.12M
Low
0.9361
Amount
158.61K
EV/EBITDA(TTM)
--
Total Shares
20.75M
EV
24.35M
EV/OCF(TTM)
--
P/S(TTM)
68.06
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Show More
Valuation Metrics
The current forward P/E ratio for Scienture Holdings Inc (SCNX.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Scienture Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q2
YoY :
-100.00%
0.00
Total Revenue
FY2025Q2
YoY :
+244.85%
-5.16M
Operating Profit
FY2025Q2
YoY :
+313.64%
-6.72M
Net Income after Tax
FY2025Q2
YoY :
-63.08%
-0.48
EPS - Diluted
FY2025Q2
YoY :
-145.74%
-2.04M
Free Cash Flow
FY2025Q2
YoY :
-274.47%
6.56
Gross Profit Margin - %
FY2025Q2
YoY :
+1549.64%
-10.22K
FCF Margin - %
FY2025Q2
YoY :
+997.77%
-95.38K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SCNX News & Events
Events Timeline
2025-08-14 (ET)
2025-08-14
09:01:56
Scienture prices 3.23M shares at $1.20 in registered direct offering
2025-08-13 (ET)
2025-08-13
08:14:47
Scienture announces shipment of launch quantities of Arbli Oral Suspension
2025-07-16 (ET)
2025-07-16
08:16:28
Scienture regains Nasdaq compliance
Sign Up For More Events
Sign Up For More Events
News
8.5
08-25SeekingAlphaScienture Holdings submits filing to sell 2.1 million shares on behalf of shareholders.
8.5
08-14NASDAQ.COMScienture Secures $3.9 Mln Through Registered Direct Stock Offering
4.5
08-14BenzingaDow Falls Over 100 Points; Deere Shares Dip After Q3 Results
Sign Up For More News
People Also Watch
FAQ
What is Scienture Holdings Inc (SCNX) stock price today?
The current price of SCNX is 0.9697 USD — it has decreased -0.72 % in the last trading day.
What is Scienture Holdings Inc (SCNX)'s business?
What is the price predicton of SCNX Stock?
What is Scienture Holdings Inc (SCNX)'s revenue for the last quarter?
What is Scienture Holdings Inc (SCNX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Scienture Holdings Inc (SCNX)'s fundamentals?
How many employees does Scienture Holdings Inc (SCNX). have?